Enhancing Transparency at the US Food and Drug Administration – Moving Beyond the 21st Century Cures Act

JAMA
April 25, 2017, Vol 317, No. 16, Pages 1595-1700
http://jama.jamanetwork.com/issue.aspx

Enhancing Transparency at the US Food and Drug Administration – Moving Beyond the 21st Century Cures Act
Joshua M. Sharfstein, MD; Michael Stebbins, PhD
JAMA. 2017;317(16):1621-1622. doi:10.1001/jama.2017.2481
This Viewpoint summarizes recommendations made in a 2017 Blueprint for Transparency at the US Food and Drug Administration developed to encourage increased public access to FDA analyses and regulatory decisions